Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system.

Ji, Chunmei; Bai, Jinmei; Zhou, Jiancheng; Zou, Ying; Yu, Mingming

Ji, Chunmei; Bai, Jinmei; Zhou, Jiancheng; Zou, Ying; Yu, Mingming.

Afiliação

Ji C; Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Bai J; Department of Respiratory, Wuxi No.5 People's Hospital, Wuxi, Jiangsu, China.
Zhou J; Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Zou Y; Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Yu M; Department of Urology, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, China.

Br J Clin Pharmacol ; 88(12): 5317-5325, 2022 12.

Article em En | MEDLINE | ID: mdl-35818959

Assuntos

Inibidores de PCSK9; Pró-Proteína Convertase 9; Humanos; Estados Unidos/epidemiologia; United States Food and Drug Administration; Mineração de Dados; Dor

Palavras-chave

FDA adverse event reporting system; PCSK9 inhibitors; adverse event; disproportionality analyses; reporting odds ratio

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pró-Proteína Convertase 9 / Inibidores de PCSK9 Tipo de estudo: Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Br J Clin Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google